Obrixtamig

Small Cell Lung Carcinoma and Other Neuroendocrine Neoplasms Expressing DLL3

Boehringer IngelheimPhase 1

—

Rating in progress

Obrixtamig in Small Cell Lung Carcinoma and Other Neuroendocrine Neoplasms Expressing DLL3 is in the Floatz rating universe. The engine has not yet published a v0.2 rating for this asset. This page will update automatically once scoring completes.

Methodology v0.2 · Active